賽微電子(300456.SZ):擬使用1億元募集資金向聚能製造出資 用於“MEMS先進封裝測試研發及產線建設項目”
格隆匯12月3日丨賽微電子(300456.SZ)公佈,公司於2021年12月3日召開第四屆董事會第十九次會議和第四屆監事會第十六次會議,審議通過了《關於使用募集資金向全資子公司出資及以房屋建築物和土地使用權向全資子公司增資的議案》,同意公司使用1億元募集資金向全資子公司北京聚能海芯半導體制造有限公司(“聚能製造”)出資,用於2020年向特定對象發行股票募集資金投資項目“MEMS先進封裝測試研發及產線建設項目”的建設,同時公司以位於北京經濟技術開發區路東區F2街區F2M3 地塊的價值1.81億元的房屋建築物和土地使用權向聚能製造增資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.